Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Isophane insulin (human), also known as NPH (Neutral Protamine Hagedorn) insulin, is an intermediate-acting, recombinant human insulin formulated as an isophane suspension with protamine sulfate. The addition of protamine sulfate slows the absorption of the insulin, resulting in a prolonged duration of action compared to regular insulin. It is structurally identical to endogenous human pancreatic insulin and functions by binding to the insulin receptor, which increases cellular glucose uptake in the liver, adipose tissue, and skeletal muscle while inhibiting hepatic glucose production. It is primarily used in the management of diabetes mellitus, including type 1 and type 2, often as a basal insulin component. In clinical trial contexts, such as those conducted by the Steno Diabetes Center, it frequently serves as a human insulin comparator against newer insulin analogues to evaluate outcomes like the incidence of severe hypoglycaemia.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on isophane insulin.